A5102706372- Cancer, Hypoxia, and Metabolism
- Cancer, Lipids, and Metabolism
- Cancer Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Autophagy in Disease and Therapy
- Immune cells in cancer
- Hippo pathway signaling and YAP/TAZ
- Bladder and Urothelial Cancer Treatments
McGill University Health Centre
2022-2023
Vessel co-option is correlated with resistance against anti-angiogenic therapy in colorectal cancer liver metastases (CRCLM). co-opting lesions are characterized by highly motile cells that move toward and along the pre-existing vessels surrounding nonmalignant tissue co-opt them to gain access nutrients. To sinusoidal vessels, vessel must displace hepatocytes occupy their space. However, mechanisms underlying this displacement unknown. Herein, we examined involvement of apoptosis,...
Colorectal cancer liver metastases (CRCLMs) have two major histopathological growth patterns (HGPs): desmoplastic (DHGP) and replacement (RHGP). The DHGP tumours derive their vasculature by angiogenesis, while the RHGP use vessel co-option. Various studies associated with an unfavourable prognosis, as well high levels of resistance to anti-angiogenic agents chemotherapy. Recently, we reported higher numbers neutrophils in tumour microenvironment (TME) co-opting compared angiogenic...
Abstract Introduction: Radical cystectomy is the standard of care for muscle invasive bladder cancer (MIBC). Radiotherapy (RT) a preserving option that offers patients comparable survival rates. However, up to 30% require salvage cystectomy. Emerging evidence points an important yet poorly understood link between response RT and tumor microenvironment (TME). Notably, tertiary lymphoid structures (TLS) are being investigated as potential local hub mounting immune response. These...